Neurotech Pharmaceuticals Unveils First and Only ENCELTO™ for Macular Telangiectasia Type 2
Neurotech Pharmaceuticals has introduced ENCELTO™ (revakinagene taroretcel-lwey) as the first and only FDA-approved treatment for adults with Macular Telangiectasia Type 2 (MacTel), a progressive neurodegenerative eye disease that leads to irreversible vision loss.
ENCELTO is an encapsulated cell therapy (ECT) implant that continuously delivers ciliary neurotrophic factor (CNTF) to the retina, helping to slow disease progression.
MacTel is characterised by retinal cell degeneration and secondary changes in retinal blood vessels, which supply oxygen and nutrients to the eye. It significantly impacts vision and quality of life.
Currently, no other approved treatments are available for this condition.
Approval was granted based on two Phase 3 clinical trials, which demonstrated that ENCELTO significantly slowed the loss of macular photoreceptors over a 24-month period.
The implant consists of a capsule containing genetically engineered retinal pigment epithelium (RPE) cells that continuously release proteins into the eye.
The semi-permeable membrane allows nutrients to enter while protecting the implanted cells from immune system attack.
ENCELTO™ is the first and only FDA-approved treatment for adults with Macular Telangiectasia Type 2 (MacTel), providing a novel therapeutic option for this vision-threatening condition.
